Year |
Citation |
Score |
2016 |
Soler DC, Young AB, Fiessinger L, Galimberti F, Debanne S, Groft S, McCormick TS, Cooper KD. Increased, but functionally impaired, CD14(+) HLA-DR(neg/low) Myeloid-Derived Suppressor Cells in psoriasis; a mechanism of dysregulated T cells. The Journal of Investigative Dermatology. PMID 26807516 DOI: 10.1016/J.Jid.2015.12.036 |
0.31 |
|
2016 |
Galimberti F, Fernandez AP. Sarcoidosis following successful treatment of pemphigus vulgaris with rituximab: a rituximab-induced reaction further supporting B-cell contribution to sarcoidosis pathogenesis? Clinical and Experimental Dermatology. 41: 413-6. PMID 26800651 DOI: 10.1111/Ced.12793 |
0.308 |
|
2015 |
Hu S, Danilov AV, Godek K, Orr B, Tafe LJ, Rodriguez-Canales J, Behrens C, Mino B, Moran CA, Memoli VA, Mustachio LM, Galimberti F, Ravi S, DeCastro A, Lu Y, et al. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. Cancer Research. 75: 2029-38. PMID 25808870 DOI: 10.1158/0008-5472.Can-14-1494 |
0.741 |
|
2014 |
Busch AM, Galimberti F, Nehls KE, Roengvoraphoj M, Sekula D, Li B, Guo Y, Direnzo J, Fiering SN, Spinella MJ, Robbins DJ, Memoli VA, Freemantle SJ, Dmitrovsky E. All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched. Cancer Biology & Therapy. 15: 463-72. PMID 24496080 DOI: 10.4161/Cbt.27821 |
0.798 |
|
2014 |
Hu S, Danilov AV, Godek KM, Orr B, Tafe LJ, Memoli VA, Galimberti F, Ravi S, DeCastro AJ, Lu Y, Mustachio LM, Sekula DJ, Andrew AS, Freemantle SJ, Compton DA, et al. Abstract 4549: CDK2 inhibition causes anaphase catastrophe through the centrosomal protein CP110 Cancer Research. 74: 4549-4549. DOI: 10.1158/1538-7445.Am2014-4549 |
0.735 |
|
2013 |
Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyengetere F, Sempere L, Beumer JH, Anyang BN, Nugent W, Johnstone D, Tsongalis GJ, Kurie JM, Li H, Direnzo J, Guo Y, et al. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Molecular Cancer Therapeutics. 12: 1545-55. PMID 23686769 DOI: 10.1158/1535-7163.Mct-12-0933 |
0.825 |
|
2013 |
Rodriguez-Blanco J, Schilling NS, Tokhunts R, Giambelli C, Long J, Liang Fei D, Singh S, Black KE, Wang Z, Galimberti F, Bejarano PA, Elliot S, Glassberg MK, Nguyen DM, Lockwood WW, et al. The hedgehog processing pathway is required for NSCLC growth and survival. Oncogene. 32: 2335-45. PMID 22733134 DOI: 10.1038/Onc.2012.243 |
0.717 |
|
2013 |
Dragnev K, Beumer J, Anyang B, Ma T, Galimberti F, Erkmen C, Nugent W, Rigas J, Abraham K, Johnstone D, Memoli V, Dmitrovsky E. A Proof-of-Principle Histone Deacetylase Inhibitor Trial in Resectable Aerodigestive Tract Cancer: Intratumoral Drug Levels and Biomarker Responses Annals of Oncology. 24: i7. DOI: 10.1093/Annonc/Mdt042.14 |
0.589 |
|
2012 |
Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, et al. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. International Journal of Oncology. 41: 1751-61. PMID 22923130 DOI: 10.3892/Ijo.2012.1599 |
0.799 |
|
2012 |
Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F, Ma T, Feng Q, Sekula D, Freemantle SJ, Andrew AS, Memoli V, Dmitrovsky E. Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Molecular Cancer Therapeutics. 11: 1968-77. PMID 22752428 DOI: 10.1158/1535-7163.Mct-12-0248 |
0.815 |
|
2012 |
Dragnev KH, Beumer JH, Anyang B, Ma T, Galimberti F, Erkmen CP, Nugent W, Rigas JR, Abraham K, Johnstone D, Memoli V, Dmitrovsky E. Vorinostat (V) intratumoral levels and biomarker response in a window of opportunity trial in patients with resectable aerodigestive tract cancer. Journal of Clinical Oncology. 30: 7022-7022. DOI: 10.1200/Jco.2012.30.15_Suppl.7022 |
0.636 |
|
2011 |
Dragnev KH, Ma T, Galimberti F, Erkmen CP, Memoli V, Nugent W, Rigas JR, Johnstone D, Frandsen A, Simeone S, Czum J, Li H, DiRenzo J, Freemantle S, Dmitrovsky E. A window-of-opportunity trial of vorinostat (V) in patients with resectable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7062. PMID 28020374 DOI: 10.1200/Jco.2011.29.15_Suppl.7062 |
0.735 |
|
2011 |
Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, et al. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prevention Research (Philadelphia, Pa.). 4: 818-28. PMID 21636548 DOI: 10.1158/1940-6207.Capr-10-0376 |
0.82 |
|
2011 |
Galimberti F, Thompson SL, Ravi S, Compton DA, Dmitrovsky E. Anaphase catastrophe is a target for cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1218-22. PMID 21288923 DOI: 10.1158/1078-0432.Ccr-10-1178 |
0.647 |
|
2011 |
Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer MA, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, et al. Abstract LB-412: Combining bexarotene with erlotinib in window of opportunity and phase II trials causes lung cancer responses independent of KRAS mutations Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-412 |
0.82 |
|
2011 |
Ma T, Galimberti F, Erkmen CP, Memoli V, Nugent W, Rigas J, Johnstone D, Li H, DiRenzo J, Freemantle S, Dragnev K, Dmitrovsky E. Abstract 342: Murine transgenic lung cancer models guide a proof of principle histone deacetylase inhibitor trial in lung cancer patients Cancer Research. 71: 342-342. DOI: 10.1158/1538-7445.Am2011-342 |
0.742 |
|
2011 |
Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Galimberti F, Ma T, Feng Q, Andrew AS, Sekula D, Freemantle S, Memoli V, Dmitrovsky E. Abstract 1655: The ubiquitin protease UBP43 is a target for lung cancer therapy and prevention Cancer Research. 71: 1655-1655. DOI: 10.1158/1538-7445.Am2011-1655 |
0.829 |
|
2011 |
Galimberti F, Busch A, Chinyengetere F, Ma T, Sekula D, Memoli V, Dragnev K, Liu F, Andrew AS, Greninger P, Robbins D, Settleman J, Benes C, Dmitrovsky E. Abstract 1615: Gene expression profile predicts response to smoothened inhibitors in epithelial cancers Cancer Research. 71: 1615-1615. DOI: 10.1158/1538-7445.Am2011-1615 |
0.817 |
|
2010 |
Guo Y, Dolinko AV, Chinyengetere F, Stanton B, Bomberger JM, Demidenko E, Zhou DC, Gallagher R, Ma T, Galimberti F, Liu X, Sekula D, Freemantle S, Dmitrovsky E. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia. Cancer Research. 70: 9875-85. PMID 20935222 DOI: 10.1158/0008-5472.Can-10-1100 |
0.78 |
|
2010 |
Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, DiRenzo J, Greninger P, Sharma SV, Settleman J, Compton DA, Dmitrovsky E. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 109-20. PMID 20028770 DOI: 10.1158/1078-0432.Ccr-09-2151 |
0.687 |
|
2010 |
Guo Y, Dolinko A, Chinyengetere F, Bomberger J, Gallagher R, Ma T, Galimberti F, Liu X, Sekula D, Busch A, Freemantle S, Dmitrovsky E. Abstract 1594: Targeting UBP43 for repression destabilizes PML/RARα and inhibits acute promyelocytic leukemia growth Cancer Research. 70: 1594-1594. DOI: 10.1158/1538-7445.Am10-1594 |
0.762 |
|
2009 |
Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Yan M, Fiering S, Memoli V, Li H, Direnzo J, Korc M, Cole CN, Bak M, Kauppinen S, et al. Uncovering growth-Suppressive micro rNAs in lung cancer Clinical Cancer Research. 15: 1177-1183. PMID 19228723 DOI: 10.1158/1078-0432.Ccr-08-1355 |
0.645 |
|
2008 |
Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, Shah SJ, Sempere LF, Memoli V, Andersen JB, Hassel BA, Dragnev K, Dmitrovsky E. UBE1L causes lung cancer growth suppression by targeting cyclin D1. Molecular Cancer Therapeutics. 7: 3780-8. PMID 19074853 DOI: 10.1158/1535-7163.Mct-08-0753 |
0.67 |
|
2007 |
Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, Kitareewan S, Dragnev KH, Dmitrovsky E. Cyclin degradation for cancer therapy and chemoprevention. Journal of Cellular Biochemistry. 102: 869-77. PMID 17868090 DOI: 10.1002/Jcb.21519 |
0.673 |
|
Low-probability matches (unlikely to be authored by this person) |
2015 |
Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. The British Journal of Dermatology. PMID 26490490 DOI: 10.1111/Bjd.14227 |
0.287 |
|
2015 |
Galimberti F, Li Y, Fernandez AP. Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis. Journal of the American Academy of Dermatology. 73: 174-6. PMID 26089058 DOI: 10.1016/J.Jaad.2015.03.047 |
0.263 |
|
2020 |
Li YM, Milikowski C, Selvaggi G, Abbo LM, Skiada D, Galimberti F. Polymyxin B-induced skin hyperpigmentation. Transplant Infectious Disease : An Official Journal of the Transplantation Society. e13312. PMID 32386075 DOI: 10.1111/Tid.13312 |
0.26 |
|
2017 |
Rajabi-Estarabadi A, Williams N, Albreakan R, Algain M, Smith SC, Dormishian A, Iglesia S, Galimberti F, Nouri K. Cells to Surgery Quiz: December 2017. The Journal of Investigative Dermatology. 137: e207. PMID 29169467 DOI: 10.1016/J.Jid.2017.10.016 |
0.255 |
|
2018 |
Rajabi-Estarabadi A, Zheng C, Iglesia S, Galimberti F, Li Y, Nouri K. Cells to Surgery Quiz: August 2018. The Journal of Investigative Dermatology. 138: e53. PMID 30032790 DOI: 10.1016/J.Jid.2018.06.172 |
0.254 |
|
2018 |
Brueggen M, Djamei V, Oro S, Wolkenstein P, Kabashima K, Li Y, Galimberti F, Romanelli P, French L. 435 IRTEN - An international registry for toxic epidermal necrolysis Journal of Investigative Dermatology. 138: S74. DOI: 10.1016/J.Jid.2018.03.442 |
0.25 |
|
2020 |
Galimberti F, McBride J, Cronin M, Li Y, Fox J, Abrouk M, Herbst A, Kirsner RS. Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19. Clinics in Dermatology. PMID 32419721 DOI: 10.1016/J.Clindermatol.2020.05.003 |
0.248 |
|
2015 |
Galimberti F, Lubelski D, Healy AT, Wang T, Abdullah KG, Nowacki AS, Benzel EC, Mroz TE. A Systematic Review of Lumbar Fusion Rates With and Without the Use of rhBMP-2. Spine. 40: 1132-9. PMID 25955186 DOI: 10.1097/Brs.0000000000000971 |
0.235 |
|
2020 |
Li YM, Milikowski C, Galimberti F. Case of Bullous Grover Disease. The American Journal of Dermatopathology. PMID 32732687 DOI: 10.1097/Dad.0000000000001756 |
0.228 |
|
2018 |
Galimberti F, Kooistra L, Li Y, Chatterjee S, Fernandez A. 540 Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis Journal of Investigative Dermatology. 138: S92. DOI: 10.1016/J.Jid.2018.03.548 |
0.221 |
|
2018 |
Galimberti F, Kooistra L, Li Y, Chatterjee S, Fernandez AP. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis. Clinical and Experimental Dermatology. PMID 29856076 DOI: 10.1111/Ced.13607 |
0.216 |
|
2020 |
Li YM, Galimberti F, Abrouk M, Kirsner RS. US Dermatology Resident Responses about the COVID-19 Pandemic: Results from a Nationwide Survey. Southern Medical Journal. 113: 462-465. PMID 32885267 DOI: 10.14423/Smj.0000000000001141 |
0.213 |
|
2016 |
Galimberti F, Guren L, Fernandez AP, Sood A. Dermatology consultations significantly contribute quality to care of hospitalized patients: a prospective study of dermatology inpatient consults at a tertiary care center. International Journal of Dermatology. PMID 27260334 DOI: 10.1111/Ijd.13327 |
0.211 |
|
2018 |
Kooistra L, Ricotti C, Galimberti F, Gota C, Fernandez AP. Malignancy-associated Dermatomyositis: Retrospective Case-Control Study From a Single Tertiary Care Center. Journal of the American Academy of Dermatology. PMID 29307640 DOI: 10.1016/J.Jaad.2018.01.002 |
0.21 |
|
2016 |
Galimberti F, Mesinkovska NA. Skin findings associated with nutritional deficiencies. Cleveland Clinic Journal of Medicine. 83: 731-739. PMID 27726828 DOI: 10.3949/Ccjm.83A.15061 |
0.2 |
|
2018 |
Sari S, Kozanhan B, Egilmez AI, Soyder A, Aydin ON, Galimberti F, Sessler D, Turan A. [The influence of the menstrual cycle on acute and persistent pain after laparoscopic cholecystectomy]. Revista Brasileira De Anestesiologia. PMID 29373141 DOI: 10.1016/J.Bjane.2017.11.001 |
0.2 |
|
2016 |
Galimberti F, Li Y, Husni E, Calabrese L, Cooper K, Fernandez A. Dermatomyositis and malignancy: A proposal for evidence-based malignancy screening guidelines: 2800 Journal of the American Academy of Dermatology. 74. DOI: 10.1016/J.Jaad.2016.02.668 |
0.196 |
|
2018 |
Galimberti F, Kamath P, Miteva M. SnapshotDx Quiz: December 2018. The Journal of Investigative Dermatology. 138: e81-e86. PMID 30466538 DOI: 10.1016/J.Jid.2018.10.002 |
0.191 |
|
2016 |
Sari S, Aydın ON, Tasdemir B, Galimberti F, Turan A. Effect of statin use on pain relief by transforaminal epidural steroid injection. The Journal of International Medical Research. 44: 389-94. PMID 26912508 DOI: 10.1177/0300060515597934 |
0.189 |
|
2014 |
Ogurlu M, Sari S, Küçük M, Bakis M, Ugur B, Eshraghi YE, Galimberti F, Turan A. Comparison of the effect of propofol and sevoflurane anaesthesia on acute and chronic postoperative pain after hysterectomy. Anaesthesia and Intensive Care. 42: 365-70. PMID 24794477 DOI: 10.1177/0310057X1404200314 |
0.187 |
|
2020 |
Li Y, Desai K, Morrison B, Galimberti F. Availability of prescription medications for sale without a prescription on the internet in the United States. International Journal of Dermatology. PMID 33232516 DOI: 10.1111/Ijd.15123 |
0.171 |
|
2020 |
Li Y, Galimberti F, Morrison B. Online availability of neurotoxin and injectable cosmetics. Journal of the American Academy of Dermatology. PMID 32948343 DOI: 10.1016/J.Jaad.2020.01.085 |
0.149 |
|
2024 |
Li YM, Galimberti F. Impact of Psoriasis on Patients' Social Network Behavior. Southern Medical Journal. 117: 115. PMID 38307510 DOI: 10.14423/SMJ.0000000000001644 |
0.12 |
|
2022 |
Li YM, Diaz-Perez JA, Obayomi A, Galimberti F, Romanelli P, Tosti A. A review of bubble hair deformity. International Journal of Dermatology. PMID 35486091 DOI: 10.1111/ijd.16200 |
0.082 |
|
2021 |
Khanna U, Galimberti F, Li Y, Fernandez AP. Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening? Annals of Translational Medicine. 9: 432. PMID 33842653 DOI: 10.21037/atm-20-5215 |
0.077 |
|
2021 |
Li YM, Desai K, Saad AG, Galimberti FV. Mycobacterium abscessus infection in a patient with ornithine transcarbamylase deficiency and liver transplant. Pediatric Dermatology. PMID 34060131 DOI: 10.1111/pde.14646 |
0.077 |
|
2021 |
Li Y, Desai K, Milikowski C, Galimberti F. Disseminated Pruritic Papules in an Adult Male: Challenge. The American Journal of Dermatopathology. 43: e115. PMID 34546992 DOI: 10.1097/DAD.0000000000001869 |
0.01 |
|
2021 |
Li Y, Desai K, Milikowski C, Galimberti F. Disseminated Pruritic Papules in an Adult Male: Answer. The American Journal of Dermatopathology. 43: 752. PMID 34546989 DOI: 10.1097/DAD.0000000000001861 |
0.01 |
|
Hide low-probability matches. |